TechConnect Wire™

 
Solving Problems for the Clean Energy Industry: Collaboration between Lawrence Berkeley National Laboratory and NIREC to Accelerate the Commercialization of Clean Energy Technologies
 This pilot program pairs NIREC's Entrepreneur-In-Residence (EIR) Program with Berkeley Lab's world-class clean energy research to meet defined market needs.
Rive Technology Raises $25 Million in Series C Financing
 Financing, Led by The Blackstone Group, to Support Commercial Trials & Global Deployment of Catalyst Technology
Cancer Targeted Technology (CTT) Enters into a Research and License Option Agreement with Bayer Pharma AG to Advance a Cancer PET Imaging Agent toward Clinical Trials
 Under the terms of the agreement, CTT will receive R&D funding and, if the option is exercised, could receive payments on the achievement of development milestones, as well as royalties on sales of products resulting from the collaboration.
Pulmatrix Receives $5.7 Million from DARPA
 Part of the 7-Day Biodefense Initiative for Development of Inhaled Therapeutics for Warfighters
Soladigm Secures $30 Million Series C Equity Financing From GE, DBL Investors, Nano Dimension and Existing Investors
 Soladigm is a developer of next-generation green building solutions designed to improve energy efficiency.
Yissum Introduces a Novel Method for Forensic DNA Profiling
 - Method enables accurate identification of a suspect's DNA in crime scenes even when DNA evidence comprises a mixture from multiple individuals -
U.S. Army Awards Researcher at Children’s Hospital Los Angeles $1.05 Million to Develop Next Generation Gene Sequencing Facility
 Whole genome characterization core facility will employ clinically applicable, state-of-the-art sequencing technology
3M to Acquire Winterthur Technologies AG
 Acquisition Enhances Abrasives Offering
Merck to Acquire SmartCells, Inc.
 SmartCells' core technology was originally developed at The Massachusetts Institute of Technology by its president, co-founder and chief executive officer Dr. Todd Zion.
UCSF Works with Anacor Pharmaceuticals and New York Blood Center to Discover Drugs for River Blindness
 The collaboration will combine Anacor’s novel boron-based chemistry platform and drug discovery and development capabilities with the Sandler Center’s expertise in neglected disease biology and drug discovery and the LFKRI’s expertise in onchocerciasis.
[ <- 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 -> ]

RSS RSS feed of TechConnect Wire™

Annual Meeting

TechConnect World 2015